Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Assanto GM, Del Giudice I, Della Starza I, Soscia R, Cavalli M, Cola M, Bellomarino V, Di Trani M, Guarini A, Foà R. Assanto GM, et al. Among authors: cavalli m. Front Oncol. 2023 Mar 14;13:1152467. doi: 10.3389/fonc.2023.1152467. eCollection 2023. Front Oncol. 2023. PMID: 36998457 Free PMC article. Review.
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, Cappelli LV, Ilari C, Cafforio L, Guarini A, Foà R. Del Giudice I, et al. Among authors: cavalli m. Front Oncol. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689. eCollection 2019. Front Oncol. 2019. PMID: 31555576 Free PMC article. Review.
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Soscia R, Della Starza I, De Novi LA, Ilari C, Ansuinelli M, Cavalli M, Bellomarino V, Cafforio L, Di Trani M, Cazzaniga G, Fazio G, Santoro A, Salemi D, Spinelli O, Tosi M, Terragna C, Robustelli V, Bellissimo T, Colafigli G, Breccia M, Chiaretti S, Di Rocco A, Martelli M, Guarini A, Del Giudice I, Foà R. Soscia R, et al. Among authors: cavalli m. Hematol Oncol. 2023 Feb;41(1):50-60. doi: 10.1002/hon.3087. Epub 2022 Oct 19. Hematol Oncol. 2023. PMID: 36251440
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance.
Della Starza I, Cavalli M, Del Giudice I, Barbero D, Mantoan B, Genuardi E, Urbano M, Mannu C, Gazzola A, Ciabatti E, Guarini A, Foà R, Galimberti S, Piccaluga P, Gaidano G, Ladetto M, Monitillo L. Della Starza I, et al. Among authors: cavalli m. Hematol Oncol. 2014 Sep;32(3):133-8. doi: 10.1002/hon.2095. Epub 2013 Nov 19. Hematol Oncol. 2014. PMID: 24254547
Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
Della Starza I, Nunes V, Cavalli M, De Novi LA, Ilari C, Apicella V, Vitale A, Testi AM, Del Giudice I, Chiaretti S, Foà R, Guarini A. Della Starza I, et al. Among authors: cavalli m. Br J Haematol. 2016 Aug;174(4):541-9. doi: 10.1111/bjh.14082. Epub 2016 May 12. Br J Haematol. 2016. PMID: 27172403 Free article.
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A. Della Starza I, et al. Among authors: cavalli m. Leuk Lymphoma. 2019 Nov;60(11):2838-2840. doi: 10.1080/10428194.2019.1607325. Epub 2019 May 3. Leuk Lymphoma. 2019. PMID: 31050551 No abstract available.
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Among authors: cavalli m. Hematol Oncol. 2019 Oct;37(4):368-374. doi: 10.1002/hon.2652. Epub 2019 Aug 16. Hematol Oncol. 2019. PMID: 31325190
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
Pulsoni A, Della Starza I, Cappelli LV, Tosti ME, Annechini G, Cavalli M, De Novi LA, D'Elia GM, Grapulin L, Guarini A, Del Giudice I, Foà R. Pulsoni A, et al. Among authors: cavalli m. Br J Haematol. 2020 Jan;188(2):249-258. doi: 10.1111/bjh.16125. Epub 2019 Aug 5. Br J Haematol. 2020. PMID: 31385309 Free article.
212 results